Evolocumab for st elevation myocardial infarction

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 17 Mar 2022: Trial registered, NCT05284747
  2. 26 Oct 2022: Trial started, NCT05284747

The trials

NCT05284747: EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction

State
Under way
Phase
Phase 4
People
6,019 taking part
Started
26 Oct 2022
Primary completion
29 May 2027
Arms
Evolocumab + Routine Lipid Management
Results
None posted
  1. 17 Mar 2022: Trial registered
  2. 26 Oct 2022: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Also known as Evolocumab 140 MG/ML [Repatha], Repatha.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.